Respiratory Assays
Respiratory CRO Services for Preclinical Drug Discovery Research
Cellomatics is a specialist respiratory CRO providing preclinical in vitro airway models to support respiratory drug discovery programmes. As a contract research organisation focused on respiratory diseases, we support biotechnology and pharmaceutical companies evaluate their therapeutic candidates using disease-relevant cellular systems and scalable screening technologies.
Our respiratory research platforms combine human airway and lung cell models, immune cell assays, and advanced imaging approaches to investigate disease mechanisms and therapeutic responses across conditions such as asthma, airway sensitisation/hyper-responsiveness, COPD, pulmonary fibrosis, viral airway infections, pulmonary hypertension and allergic airway disease.
By integrating disease-relevant biology with scalable screening workflows, Cellomatics helps partners accelerate target validation, hit identification and lead optimisation in respiratory drug discovery.
What is a respiratory CRO?
A respiratory contract research organisation (CRO) provides specialised scientific services that support the discovery and development of therapies targeting airway diseases.
These organisations work as research partners for biotechs and pharmaceutical companies, providing access to disease-relevant experimental models, screening platforms and translational expertise that enable the evaluation of new drug candidates before clinical development.
At Cellomatics, our respiratory CRO services focus on human-relevant in vitro models and cellular assays designed to replicate key biological processes involved in respiratory disease. These systems allow researchers to study disease mechanisms, evaluate compound activity and generate robust data that supports decision-making throughout early drug discovery.
Respiratory disease expertise
Cellomatics supports respiratory research programmes across a range of airway diseases. Our scientific platforms combine human lung and airway cell systems, immune cell models and scalable screening technologies to generate high-quality data for respiratory drug discovery.
Our flexible respiratory assay systems can be adapted to specific targets, pathways and compound screening strategies, allowing researchers to investigate disease mechanisms, inflammatory signalling and therapeutic responses across multiple pulmonary conditions.
Asthma and Airway Inflammation
Pulmonary Fibrosis
Chronic Obstructive Pulmonary Disease
Allergic Respiratory Conditions
Viral Respiratory Infections
Expert insight: asthma and airway inflammation research
To explore current scientific perspectives in this area, listen to our podcast featuring Dr Eleni Birli, who discusses her research on asthma and airway inflammation and how emerging scientific insights are shaping respiratory disease research.
Screening and assay capabilities
Cellomatics provides advanced screening and assay capabilities designed to support respiratory drug discovery programmes from early target validation through lead optimisation. Our platforms combine disease-relevant biology with scalable experimental systems, enabling detailed evaluation of compound activity, mechanism of action, and therapeutic potential. By integrating cell-based respiratory models, imaging technologies, and automated workflows, we generate high-quality, reproducible data to guide confident decision-making across discovery pipelines.
Cell-Based Respiratory Screening
High-Throughput & High-Content Screening
Human-relevant in vitro respiratory models
Cellomatics develops human-relevant in vitro respiratory models designed to replicate key biological processes within the airway environment. These systems use well-characterised human respiratory cells, including airway epithelial and smooth muscle/myofibroblastmodels, to capture clinically relevant aspects of respiratory disease biology.
Our models allow detailed investigation of inflammatory signalling, immune responses and tissue remodelling associated with respiratory disorders. By integrating human cell biology with advanced imaging and assay technologies, we generate translational data that helps researchers better predict therapeutic responses during respiratory drug development.
Why choose Cellomatics as your respiratory CRO?
Cellomatics provides specialised expertise in in vitro respiratory models to support drug discovery programmes targeting lung and airway diseases.
Our scientific teams work closely with biotechnology and pharmaceutical partners to design assay strategies aligned with specific targets, mechanisms and project goals.
Key advantages include:
- Human-relevant respiratory models using well-characterised lung and airway cell systems
- Flexible assay development tailored to specific targets, pathways, and screening needs
- Collaborative scientific support delivering robust, decision-driving preclinical data
Request more information
For a more in depth look at our respiratory expertise, click the button below to gain access to our Respiratory Hub with a detailed look at our data sets and offering.
Respiratory CRO – Frequently asked questions
1. What respiratory CRO services does Cellomatics provide?
Cellomatics offers a range of respiratory CRO services designed to support early drug discovery and translational research. Common respiratory research services include in vitro respiratory disease models, cell-based screening assays, primary human cell assays, immune cell studies, and high-content or high-throughput screening. These platforms enable detailed evaluation of compound activity, mechanism of action, and therapeutic potential in lung and airway disease models.
2. Do you support preclinical respiratory drug discovery?
Yes. Cellomatics supports preclinical respiratory drug discovery programmes, helping biotech and pharmaceutical teams evaluate therapeutic candidates before clinical development. Our models generate robust data to guide target validation, compound screening, and lead optimisation.
3. Which respiratory diseases do you work in?
Our research platforms support studies in multiple respiratory diseases, including asthma, airway inflammation, pulmonary fibrosis, COPD, viral infection and allergic respiratory conditions.
4. Do you offer cell-based and high-throughput screening?
Yes. We provide cell-based respiratory screening assays, alongside high-throughput and high-content screening platforms suitable for both targeted studies and larger compound libraries.
5. Are your respiratory CRO services UK-based?
Yes. Cellomatics delivers respiratory CRO services in the UK, supporting global partners with flexible, collaborative preclinical research services.
Request a consultation with Cellomatics Biosciences today
Our experienced team of in vitro laboratory scientists will work with you to understand your project and provide a bespoke project plan with a professional, flexible service and a fast turnaround time.
To request a consultation where we can discuss your exact requirements, please contact Cellomatics Biosciences.
